Alnylam Pharmaceuticals Inc
NASDAQ: ALNY · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Alnylam Pharmaceuticals Inc (ALNY) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.93M | $50.90M | $96.16M | $100.53M | $100.04M | $82.76M | $66.72M | $47.17M | $50.56M | $41.10M | $47.16M | $89.91M | $74.91M | $219.75M | $492.85M | $844.29M | $1.04B | $1.83B | $2.25B | $3.71B |
| Revenue growth (YoY) | — | +89.0% | +88.9% | +4.5% | -0.5% | -17.3% | -19.4% | -29.3% | +7.2% | -18.7% | +14.8% | +90.7% | -16.7% | +193.4% | +124.3% | +71.3% | +22.9% | +76.2% | +23.0% | +65.2% |
| Cost of revenue | $62.62M | $136.19M | $118.40M | $142.65M | $136.98M | $132.45M | $122.87M | $134.19M | $229.78M | $330.40M | $462.15M | $578.10M | $1.80M | $25.06M | $78.05M | $140.14M | $168.82M | $310.41M | $323.37M | $677.17M |
| Gross profit | $26.93M | $50.90M | $96.16M | $100.53M | $100.04M | $82.76M | $66.72M | $47.17M | $50.56M | $41.10M | $47.16M | $89.91M | $73.11M | $194.69M | $414.80M | $704.14M | $868.60M | $1.52B | $1.92B | $3.04B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.6% | 88.6% | 84.2% | 83.4% | 83.7% | 83.0% | 85.6% | 81.8% |
| R&D | $49.80M | $120.69M | $96.88M | $108.73M | $106.38M | $99.30M | $86.57M | $112.96M | $190.25M | $276.50M | $382.39M | $390.63M | $505.42M | $655.11M | $654.82M | $792.16M | $883.01M | $1.00B | $1.13B | $1.32B |
| SG&A | $16.63M | $23.39M | $27.11M | $39.91M | $37.73M | $38.28M | $44.61M | $27.15M | $44.53M | $60.61M | $89.35M | $199.37M | $382.36M | $479.00M | $588.42M | $620.64M | $770.66M | $795.65M | $975.53M | $1.21B |
| Operating income | $-39.50M | $-93.18M | $-27.84M | $-48.11M | $-44.07M | $-54.82M | $-129.46M | $-92.94M | $-404.98M | $-296.01M | $-424.59M | $-500.09M | $-814.67M | $-939.43M | $-828.44M | $-708.65M | $-785.07M | $-282.18M | $-176.88M | $501.58M |
| Operating margin | -146.7% | -183.1% | -28.9% | -47.9% | -44.1% | -66.2% | -194.0% | -197.0% | -801.0% | -720.3% | -900.3% | -556.2% | -1087.6% | -427.5% | -168.1% | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% |
| EBITDA | $-35.69M | $-75.06M | $-18.93M | $-41.02M | $-38.06M | $-49.69M | $-51.71M | $-82.71M | $-172.29M | $-276.96M | $-409.46M | $-486.72M | $-754.24M | $-885.06M | $-736.33M | $-661.56M | $-926.56M | $-258.24M | $-178.85M | $557.24M |
| EBITDA margin | -132.5% | -147.5% | -19.7% | -40.8% | -38.0% | -60.0% | -77.5% | -175.4% | -340.8% | -673.9% | -868.2% | -541.3% | -1006.9% | -402.8% | -149.4% | -78.4% | -89.3% | -14.1% | -8.0% | 15.0% |
| EBIT | $-39.50M | $-79.14M | $-24.66M | $-47.01M | $-43.00M | $-54.82M | $-60.75M | $-92.94M | $-184.21M | $-296.01M | $-424.59M | $-500.09M | $-760.67M | $-939.43M | $-771.10M | $-709.12M | $-971.02M | $-312.30M | $-235.52M | $501.58M |
| Interest expense | $1.03M | $1.08M | $872000.00 | $5.38M | $2.31M | $1.21M | $977000.00 | $1.07M | $2.56M | $5.86M | $8.31M | $12.24M | $29.26M | $108.55M | $84.50M | $143.02M | $155.97M | $121.22M | $141.86M | $252.63M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-34.61M | $-85.47M | $-26.25M | $-47.59M | $-43.52M | $-57.65M | $-106.01M | $-89.22M | $-360.39M | $-290.07M | $-410.11M | $-490.87M | $-761.50M | $-886.12M | $-858.28M | $-852.82M | $-1.13B | $-440.24M | $-278.16M | $313.75M |
| Net income growth (YoY) | — | -147.0% | +69.3% | -81.3% | +8.6% | -32.5% | -83.9% | +15.8% | -303.9% | +19.5% | -41.4% | -19.7% | -55.1% | -16.4% | +3.1% | +0.6% | -32.6% | +61.1% | +36.8% | +212.8% |
| Profit margin | -128.5% | -167.9% | -27.3% | -47.3% | -43.5% | -69.7% | -158.9% | -189.2% | -712.8% | -705.8% | -869.6% | -545.9% | -1016.6% | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
Frequently asked questions
What is Alnylam Pharmaceuticals Inc's revenue?
Alnylam Pharmaceuticals Inc's trailing twelve-month revenue is $4.29B, and consensus projects about $13.92B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is ALNY?
In its most recent fiscal year, ALNY ran a gross margin of 81.77%, an operating margin of 13.51%, and a net margin of 8.45%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does ALNY generate?
ALNY produced $465.38M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ALNY's balance sheet healthy?
ALNY holds $1.66B in cash and equivalents against $1.01B in long-term debt, on $789.18M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.